Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) is anticipated to issue its resultson Tuesday, August 18th. Analysts expect Sorrento Therapeutics to post earnings of ($0.3650) per share and revenue of $8.3740 million for the quarter.
Sorrento Therapeutics Stock Performance
NASDAQ:SRNE opened at $0.00 on Tuesday. The firm has a market capitalization of $220,512.00, a price-to-earnings ratio of -0.00 and a beta of 0.13. Sorrento Therapeutics has a one year low of $0.00 and a one year high of $0.10.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of therapies in immuno-oncology, inflammatory diseases and pain management. Leveraging proprietary antibody, small molecule and cell therapy platforms, Sorrento aims to advance next-generation treatment candidates that address unmet medical needs in oncology and chronic pain without reliance on traditional opioids.
The company’s immuno-oncology pipeline encompasses monoclonal antibodies, antibody-drug conjugates and engineered cell therapies designed to target solid tumors and hematologic malignancies.
See Also
- Five stocks we like better than Sorrento Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
